Skip to main content

Table 2 Association of placement of permanent vascular access with attribution of end-stage renal disease to systemic lupus erythematosus vs. other causes, among U.S. incident hemodialysis patients who started dialysis in 2010 with only a catheter in place

From: Comparison of vascular access outcomes in patients with end-stage renal disease attributed to systemic lupus erythematosus vs. other causes: a retrospective cohort study

Model

No. (%) with permanent access placed within 1 year

Hazard ratio (95 % CI) for placement of permanent vascular access, SLE-attributed vs. other ESRD

Unadjusted

Adjusted for demographics

Adjusted for demographics + clinical

All events

    

 SLE-attributed ESRD

177 (46.1 %)

0.74 (0.64-0.86)

0.94 (0.81-1.09)

1.00 (0.86-1.17)

 Other ESRD

22,076 (54.5 %)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

P

0.001

<0.001

0.42

>0.9

All AVF placementsa

    

 SLE-attributed ESRD

137 (35.7 %)

0.73 (0.62-0.87)

0.93 (0.79-1.11)

1.00 (0.84-1.18)

 Other ESRD

17,300 (42.7 %)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

P

0.006

<0.001

0.43

>0.9

All AVG placementsa

    

 SLE-attributed ESRD

40 (10.4 %)

0.77 (0.56-1.05)

1.00 (0.73-1.38)

1.06 (0.77-1.47)

 Other ESRD

4,776 (11.8 %)

1.00 (ref.)

1.00 (ref.)

1.00 (ref.)

P

0.41

0.10

>0.9

0.71

  1. AVF arteriovenous fistula, AVG arteriovenous graft, ESRD end-stage renal disease, SLE systemic lupus eythematosus. Demographics: age (continuous), sex, race; clinical: body mass index (continuous), smoking, congestive heart failure, diabetes, and peripheral vascular disease
  2. aTime-to-event analyses censored for placement of other type of access